Literature DB >> 18475149

Urotensin II induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta.

Yong-Gang Zhang1, Jun Li, Yu-Guang Li, Rui-Hong Wei.   

Abstract

BACKGROUND: Urotensin II is a new potent vasoconstrictor. Nevertheless, little is known about its effects on the activation of adventitial fibroblasts.
OBJECTIVE: To explore the effects of urotensin II on phenotypic differentiation, migration, and collagen I synthesis of rat aortic adventitial fibroblasts.
METHODS: Growth-arrested adventitial fibroblasts were incubated in serum-free medium with urotensin II and some inhibitors of signal transduction pathways. The alpha-smooth muscle-actin expression, collagen I synthesis and migration of adventitial fibroblasts induced by urotensin II were evaluated by western blot, enzyme-linked immunosorbant assay, and the transwell technique, respectively.
RESULTS: Urotensin II induced the [alpha]-smooth muscle-actin expression in a dose-dependent and time-dependent manner, with maximal effect at a concentration of 10(-8) mol/l at 24 h (79.9%); it also caused a dose-dependent increase in collagen I synthesis, with maximal effect at a concentration of 10(-7) mol/l (42.6%). The Ca2+ channel blocker nicardipine (10(-5) mol/l), protein kinase C inhibitor H7 (10(-5) mol/l), Rho protein kinase inhibitor Y-27632 (10(-5) mol/l), calcineurin inhibitor cyclosporine A (10(-5) mol/l), and mitogen-activated protein kinase inhibitor PD98059 (10(-5) mol/l) inhibited urotensin II-induced increases in [alpha]-smooth muscle-actin expression and collagen synthesis. Meanwhile, urotensin II stimulated the migration of adventitial fibroblasts dose dependently, with maximal effect at a concentration of 10(-8) mol/l, which was 5.7-fold greater than that of the control. This effect could also be inhibited by PD98059, H7, cyclosporine A, and Y-27632 but not nicardipine.
CONCLUSION: Urotensin II may stimulate adventitial fibroblasts phenotypic conversion, migration, and collagen I synthesis through the protein kinase C, mitogen-activated protein kinase, calcineurin, Rho kinase, and/or Ca2+ signal transduction pathways, contributing to the development of vascular remodeling through adventitial fibroblasts activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18475149     DOI: 10.1097/HJH.0b013e3282fa1412

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  15 in total

1.  Vascular smooth muscle cell motility: From migration to invasion.

Authors:  Sherif F Louis; Peter Zahradka
Journal:  Exp Clin Cardiol       Date:  2010

2.  Crucial genes and pathways in chicken germ stem cell differentiation.

Authors:  Zhentao Zhang; Ahmed Kamel Elsayed; Qingqing Shi; Yani Zhang; Qisheng Zuo; Dong Li; Chao Lian; Beibei Tang; Tianrong Xiao; Qi Xu; Guobin Chang; Guohong Chen; Lei Zhang; Kehua Wang; Yingjie Wang; Kai Jin; Yilin Wang; Jiuzhou Song; Hengmi Cui; Bichun Li
Journal:  J Biol Chem       Date:  2015-04-06       Impact factor: 5.157

3.  Chemotactic G protein-coupled receptors control cell migration by repressing autophagosome biogenesis.

Authors:  Pierre-Michaël Coly; Nicolas Perzo; Vadim Le Joncour; Céline Lecointre; Marie-Thérèse Schouft; Laurence Desrues; Marie-Christine Tonon; Olivier Wurtz; Pierrick Gandolfo; Hélène Castel; Fabrice Morin
Journal:  Autophagy       Date:  2016-10-07       Impact factor: 16.016

4.  Urotensin 2 in Kawasaki disease pathogenesis.

Authors:  Cassidy Y Huang; Jane C Burns; Chisato Shimizu
Journal:  Pediatr Res       Date:  2017-08-16       Impact factor: 3.756

5.  Discovery of new antagonists aimed at discriminating UII and URP-mediated biological activities: insight into UII and URP receptor activation.

Authors:  D Chatenet; M Létourneau; Q T Nguyen; N D Doan; J Dupuis; A Fournier
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

6.  Signaling switch of the urotensin II vasosactive peptide GPCR: prototypic chemotaxic mechanism in glioma.

Authors:  C Lecointre; L Desrues; J E Joubert; N Perzo; P-O Guichet; V Le Joncour; C Brulé; M Chabbert; R Leduc; L Prézeau; A Laquerrière; F Proust; P Gandolfo; F Morin; H Castel
Journal:  Oncogene       Date:  2015-01-19       Impact factor: 9.867

7.  Can early myocardial infarction-related deaths be diagnosed using postmortem urotensin receptor expression levels?

Authors:  Mustafa Talip Sener; Emre Karakus; Zekai Halici; Erol Akpinar; Atilla Topcu; Ahmet Nezih Kok
Journal:  Forensic Sci Med Pathol       Date:  2014-06-18       Impact factor: 2.007

8.  Effect of CTRP3 on activation of adventitial fibroblasts induced by TGF-β1 from rat aorta in vitro.

Authors:  Shaohui Lin; Shaojun Ma; Ping Lu; Wenwei Cai; Yi Chen; Jing Sheng
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

9.  A closer look at the role of urotensin II in the metabolic syndrome.

Authors:  Pierre-Olivier Barrette; Adel Giaid Schwertani
Journal:  Front Endocrinol (Lausanne)       Date:  2012-12-28       Impact factor: 5.555

10.  Update on the urotensinergic system: new trends in receptor localization, activation, and drug design.

Authors:  David Chatenet; Thi-Tuyet M Nguyen; Myriam Létourneau; Alain Fournier
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-02       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.